«A general message from these studies is that cancer cells benefit from modulating epigenetic factors like SIRT6
by acquiring the ability to override
normal cellular
growth control
patterns,» says Mostoslavsky, an associate professor of Medicine at Harvard Medical School and an associate member at the Broad Institute.